Sertraline (SSRI)
Treatment for Anxiety Disorder
Typical Dosage: 50-200mg daily
Effectiveness
75%
Safety Score
60%
Clinical Trials
250
Participants
40K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
50-200mg daily
Time to Effect
2-4 weeks
Treatment Duration
6-12 months, often longer
Evidence Quality
HIGHNumber Needed to Treat (NNT)
5(Treat 5 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
10(Treat 10 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$300
Monitoring:$200
Side Effect Mgmt:$100
Total Annual:$600
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$45,000/QALY
QALYs Gained
0.25
Outcome-Based Costs
Cost per Responder
$1,000
Cost per Remission
$1,714
Comparison vs No Treatment
Cost Difference
+$600/year
More expensive
QALY Difference
+0.25 QALYs
Better outcomes
Dominance
No dominance
Sertraline (SSRI) Outcomes
for Anxiety Disorder
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+60%
Remission Rate
+35%
Common Side Effects
Nausea
+20%
Diarrhea
+15%
Insomnia
+12%
Sexual dysfunction
+30%
Active Clinical Trials
4 active trials recruiting for Sertraline (SSRI) in Anxiety Disorder
Comparison of the Effectiveness Level of Virtual Reality Exposure Therapy With Sertraline Treatment in Social Anxiety Disorder
NCT07192367RECRUITINGPHASE4
56 participants
INTERVENTIONAL
Kocaeli, Turkey (Türkiye)
Started: Nov 15, 2024
Partners in Caring for Anxious Youth
NCT04598230ACTIVE NOT RECRUITINGPHASE3
468 participants
INTERVENTIONAL
Los Angeles, United States +2 more
Started: Feb 9, 2021
Trial With the Treatment of Sertraline in Youth With Generalized, Separation and/or Social Anxiety Disorders.
NCT04221997RECRUITINGPHASE4
150 participants
INTERVENTIONAL
Cincinnati, United States
Started: Nov 1, 2019
Pharmaco(Epi)Genetic, Proteomic, and Microbiomic Study of Obsessive-Compulsive Disorder
NCT02431845RECRUITINGNA
200 participants
INTERVENTIONAL
Seoul, South Korea
Started: Jan 1, 2013
Completed Clinical Trials
11 completed trials for Sertraline (SSRI) in Anxiety Disorder
Effect of Lactobacillus Plantarum 299v Supplementation on Major Depression Treatment
NCT02469545COMPLETEDPHASE2
60 participants
INTERVENTIONAL
Bialystok, Poland
Started: Jun 1, 2014
Quetiapine Augmentation Versus Clomipramine Augmentation of SSRI for Obsessive-compulsive Disorder Patients
NCT00564564COMPLETEDPHASE4
21 participants
INTERVENTIONAL
São Paulo, Brazil
Started: Jan 1, 2006
Brain Markers of Anxiety Disorders and SSRI/CBT Treatment in Children and Adolescents
NCT01160588COMPLETED
156 participants
OBSERVATIONAL
Ann Arbor, United States
Started: Jul 1, 2010
Identifying Brain and Genetic Markers of Sertraline Treatment Response in People With Social Anxiety Disorder
NCT00872131COMPLETED
200 participants
OBSERVATIONAL
Ann Arbor, United States
Started: Mar 1, 2008
The Gut Microbiota in Obsessive-Compulsive Disorder
NCT02285699COMPLETEDNA
43 participants
INTERVENTIONAL
Hamilton, Canada
Started: Nov 1, 2014
Evaluation of Stress Disorders
NCT00050804COMPLETEDPHASE4
80 participants
INTERVENTIONAL
Bethesda, United States
Started: Dec 1, 2002
Negative Valence Brain Targets and Predictors of Anxiety and Depression Treatment
NCT01903447COMPLETEDPHASE4
271 participants
INTERVENTIONAL
Chicago, United States
Started: Dec 13, 2013
Combined Mirtazapine and SSRI Treatment of PTSD: A Placebo-Controlled Trial
NCT01178671COMPLETEDPHASE4
38 participants
INTERVENTIONAL
New York, United States
Started: Jul 1, 2010
Predicting Treatment Response in Patients With OCD
NCT03993535COMPLETEDPHASE4
250 participants
INTERVENTIONAL
New York, United States +3 more
Started: Oct 10, 2018
Effectiveness of Sertraline and Cognitive Behavioral Therapy in Treating Pediatric Obsessive-Compulsive Disorder
NCT00382291COMPLETEDPHASE4
56 participants
INTERVENTIONAL
Gainesville, United States +1 more
Started: Feb 1, 2009
Risperidone Augmentation for PTSD
NCT00215241COMPLETEDPHASE2, PHASE3
80 participants
INTERVENTIONAL
Atlanta, United States +1 more
Started: Apr 1, 2004
Showing 20 of 31 total trials